falsefalse

Dr Ku on the Safety Profile of JNJ-90014496 in Relapsed/Refractory LBCL

Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, discusses safety and efficacy findings with JNJ-90014496 in relapsed/refractory large B-cell lymphoma.

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected

    Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital, discussed safety and efficacy findings from a phase 1b trial (NCT05421663) investigating the CD19/CD20–directed bispecific CAR T-cell therapy JNJ-90014496 in patients with relapsed/refractory large B-cell lymphoma.


    x